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ABSTRACT: Angiotensin I-converting enzyme (ACE) is central to the regulation of the renin-angiotensin
system and is a key therapeutic target for combating hypertension and related cardiovascular diseases.
Currently available drugs bind both active sites of its two homologous domains, although it is now
understood that these domains function differently in vivo. The recently solved crystal structures of both
domains (N and C) open the door to new domain-specific inhibitor design, taking advantage of the
differences between these two large active sites. Here we present the first crystal structure at a resolution
of 2.25 Å of testis ACE (identical to the C domain of somatic ACE) with the highly C-domain-specific
phosphinic inhibitor, RXPA380. Testis ACE retains the same conformation as seen in previously determined
inhibitor complexes, but the RXPA380 central backbone conformation is more similar to that seen for the
inhibitor captopril than enalaprilat. The RXPA380 molecule occupies more subsites of the testis ACE
active site than the previously determined inhibitors and possesses bulky moieties that extend into the S2′
and S2 subsites. Thus the high affinity of RXPA380 for the testis ACE/somatic ACE C domain is explained
by the interaction of these bulky moieties with residues unique to these domains, specifically Phe 391,
Val 379, and Val 380, that are not found in the N domain. The characterization of the extended active site
and the binding of a potent C-domain-selective inhibitor provide the first structural data for the design of
truly domain-specific pharmacophores.
Angiotensin I-converting enzyme (ACE)1 is a zinc met-
allopeptidase and a major drug target for cardiovascular
disease. It has a central role in the renin-angiotensin system
(RAS), regulating blood pressure, fluid and electrolyte
homeostasis, and renal and vascular function, through its
ability to produce angiotensin II from the precursor decapep-
tide angiotensin I and to inactivate bradykinin. As such, it
is a key therapeutic target for the treatment of hypertension,
congestive heart failure, myocardial infarction, renal failure,
and diabetic nephropathy (1). Somatic ACE (sACE) is a
monomeric, membrane-tethered protein, located on the
plasma membrane of epithelial cells. It has two enzymatic
domains, termed the N and C domains, and is heavily
glycosylated (2). A second form of ACE is found in the testis,
termed testis ACE (tACE), and plays an important role in
fertilization (3). This is also a membrane-bound protein but
consists of only one enzymatic domain and a short heavily
O-glycosylated N-terminal sequence (4).
Initial drug development for ACE was an early success
for rational drug design, in the absence of the 3D structure
for ACE (5). The simultaneous development of ACE
inhibitors captopril and enalapril was based on the structures
of carboxypeptidase A and thermolysin. These drugs have
been hugely successful, even though the recent ACE crystal
structure did not show significant structural similarity to
either of these enzymes (6). Furthermore, it has become
apparent since the advent of these drugs that sACE has the
two homologous, but not identical, N and C enzymatic
domains (7). These two domains both cleave angiotensin I
and bradykinin but have different specificities for other
substrates and inhibitors. The C domain is more efficient at
cleaving the substrate Hip-His-Leu (HHL) (8) whereas the
N domain has a preference for Ang1-7 (9) and Ac-Ser-
Asp-Lys-Pro (AcSDKP) (10). They also differ in their
glycosylation patterns and chloride activation (8, 11). These
data suggest that the two domains might have different
physiological roles. Indeed, the N domain contributes to the
regulation of hematopoietic stem cell differentiation and
proliferation through its hydrolysis of AcSDKP (10, 12),
whereas the C domain is sufficient to maintain the regulation
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of the renin-angiotensin system (13). Therefore, it has been
postulated that the use of domain-specific inhibitors may
allow more precise control of ACE activities for specific
therapeutic use and possibly reduce side effects such as cough
and angioedema (14). Angioedema and cough are widely
accepted to be caused by raised levels of bradykinin
(15-17), and whereas angiotensin I cleavage is inhibited
by blockage of either of the active sites, bradykinin can
still be degraded if one of the active sites is unoccupied
(18).
To further elucidate the significance of these two active
sites, two new domain-specific inhibitors based on phosphinic
peptides have been developed. All ACE inhibitors to date
have been peptide analogues, usually with a sulfhydryl
(captopril), carboxyl (lisinopril/enalaprilat), or ketone (keto-
ACE) group for coordination of the zinc ion (19). Phosphinic
peptides have been shown to have an advantage over the
traditional inhibitors in terms of selectivity, due to the weaker
coordinating power of the phosphate toward the zinc ion,
allowing binding to be regulated by other determinants of
the molecule (20). Initially, an N-domain-specific inhibitor
was developed, RXP407, with a Ki for the N domain of 7
nM, 1000 times lower than for the C domain (21). Further-
more, RXP407 upregulated AcSDKP metabolism, increasing
its plasma levels by 4-6-fold with no effect on blood
pressure regulation (22). This was followed by RXPA380,
a specific inhibitor for the C domain, which has a Ki of 3
nM for the C domain, 3000 times lower than for the N
domain (18). In order to study the structural basis for this
difference in domain selectivity between these inhibitors, we
have crystallized tACE, which is identical to the C domain
of sACE, with the RXPA380 inhibitor.
EXPERIMENTAL PROCEDURES
Purification. A variant of human tACE (tACE¢36NJ) was
expressed in CHO cells and purified to homogeneity using
lisinopril-Sepharose affinity chromatography, as described
previously (23). We refer to this variant throughout the
manuscript as tACE. tACE activity was determined by
measuring the hydrolysis of hippuryl-histidyl-leucine (Sigma)
in a fluorometric assay (24). Protein concentration was
determined by a Bradford protein assay (Bio-Rad protein
microassay). Synthesis of RXPA380 [(2S)-2-[({2-[(1R)-1-
[((benzyloxy)carbonyl)amino]-2-(phenylethyl)(hydroxyl)-
phosphinyl]cyclopentyl}carbonyl)amino]-3-(1H-indol-3-yl)-
propionic acid (Cbz-Phe¾[P(O)(OH)CH]Pro-Trp-OH)] was
as described previously (25).
Crystallization and Data Collection. Equal volumes of
tACE (6.4 mg/mL in 10 mM Hepes, pH 7.5) and RXPA380
(2 mM in water) were incubated on ice for 4 h. One
microliter of this mixture was mixed with an equal volume
of reservoir solution (13.5% PEG 4000, 0.12 M sodium
malonate, 90 mM sodium acetate, pH 4.7, and 9 íM zinc
sulfate) and suspended above the well as a hanging drop at
16 °C. Crystals grew within a couple of days. A single crystal
was cryocooled (100 K) using reservoir solution plus 25%
(v/v) glycerol as a cryoprotectant. Diffraction data to 2.25
Å were collected on station X13 of DESY in Hamburg and
a low-resolution dataset at BM14 of ESRF in Grenoble. The
data were processed and scaled in HKL2000 (26) (see Table
1). The symmetry and systematic absences were consistent
with the spacegroup P212121 (unit cell dimensions a ) 56.47
Å, b ) 84.75 Å, and c ) 133.51 Å) with one molecule in
the asymmetric unit. Data reduction was carried out using
the CCP4 program TRUNCATE (27).
Structure Determination. The atomic coordinates of tACE
were used as the starting model (PDB code 1O8A) (6).
Refinement was carried out with Refmac (28), with 4% of
the reflections kept aside for Rfree calculation (29). Model
building, including the addition of RXPA380 and water
molecules, was done with Coot (30). Figures were produced
with PYMOL (DeLano Scientific, San Carlos, CA).
RESULTS
OVerall Structure. The tACE domain forms an ellipsoid
with the active site buried in the center. In all structures
determined so far it retains the same closed conformation
associated with inhibitor binding (6, 31), although it has been
proposed to flex in a manner similar to that observed for
ACE2 to provide access to the active site (32, 33). Of the
total construct, residues 37-627 and residues 40-623 are
observed in the crystal structure. This includes an additional
six C-terminal residues to those observed for the other native
and ligand-bound tACE structures, but which were observed
for the tACE-g13 glycosylation mutant structure (32).
Interestingly, no sugars were observed at any of the six
glycosylation sites, possibly because of the lower resolution
of this structure.
Binding of RXPA380. RXPA380 (Figure 1A) is the longest
inhibitor whose 3D structure in complex with tACE has been
solved using X-ray crystallography. This phosphinic peptide
not only has residues occupying the S2′, S1′, and S1 subsites
(Trp, Pro, and Phe, respectively) but also has a second Phe
moiety extending into the S2 subsite. RXPA380 binds the
active site in an elongated conformation, with both phos-
phinyl oxygens coordinating the zinc (Figure 1B). The
RXPA380 is positioned by eight direct hydrogen bonds with
the protein, as calculated by HBPLUS (34), including three
with the phosphinyl oxygens (Figure 2A) (Table 2). The
N-terminus is positioned by an aromatic interaction with Phe
391 and a hydrogen bond between the carbonyl oxygen
Table 1: Crystallographic Data
resolution range, Å 20-2.25
space group P212121
no. of reflections measured 278277
no. of unique reflections 22494
I/ó(I) (outer shell)a 7.1 (1.5)
completeness (outer shell),a % 72.2 (59.1)
Rsymmb (outer shell),a % 10.3 (46.1)
Rcrystc (last shell), % 21.5 (31.9)
Rfreed (last shell), % 26.2 (41.9)
average temperature factor, Å2
protein atoms 22.4
RXPA380 17.6
solvent (no. of water molecules) 15.8 (107)
deviation from ideal values (rms)
bond lengths, Å 0.008
bond angles, deg 1.2
a Outer shell, 2.33-2.25 Å. b Rsymm ) ∑h∑i[jIi(h) - 〈I(h)〉j/∑h∑iIi(h)],
where Ii is the ith measurement and 〈I(h)〉 is the weighted mean of all
measurements of I(h). c Rcryst ) ∑hjFo - Fcj/∑hFo, where Fo and Fc are
the observed and calculated structure factor amplitudes of reflection h,
respectively. d Rfree is equal to Rcryst for a randomly selected 4% subset
of reflections not used in the refinement.
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between the two Phe moieties and the backbone nitrogen of
Ala 356. In contrast, the carbonyl oxygen on the C-terminal
side makes two hydrogen bonds with His 353 and His 513.
Finally, one oxygen of the C-terminal carboxylate is anchored
by Lys 511 and Tyr 520, while the other oxygen makes a
hydrogen bond with a water molecule.
Comparison with Other Known Inhibitors. Superposition
of the RXPA380 structure with the previously determined
structures of captopril, enalaprilat, and lisinopril shows a
similar, but not identical, conformation to these peptide
mimics (Figure 2B,C). The C-terminus is almost identically
placed in all four complexes, interacting with Lys 511 and
Tyr 520. Despite the differences in the zinc coordination
moieties (carboxyl in the case of enalaprilat and lisinopril,
sulfhydryl for captopril, and phosphate for RXPA380) the
inhibitor coordinating atoms are similarly positioned. The
two phosphinyl oxygens of RXPA380 overlap almost
precisely with those from the carboxylate groups of enala-
prilat and lisinopril, with one 2 Å away and the other 2.5
Å away from the zinc. The P1 Phe moieties of RXPA380,
lisinopril, and enalaprilat also occupy the same space,
although the difference in the backbone composition results
in a slightly different angling of this substituent. Interestingly,
the backbone of RXPA380 most closely follows the back-
bone conformation of captopril on the C-terminal side of
the zinc-binding group. In the case of lisinopril and enala-
prilat, the backbone bends away from the zinc to leave space
to accommodate the longer carboxyl moiety next to the zinc
(Figure 2C). RXPA380 makes eight hydrogen bonds with
the protein, one more than enalaprilat and three more than
captopril. Of these, however, four are conserved between
all the inhibitors. These are the interactions of the C-terminal
carboxyl and the adjacent carbonyl oxygen moieties with
Lys 511 and Tyr 520 and with His 353 and His 513,
respectively. In addition, the carboxylic acid is observed to
bind a water molecule in all four inhibitor structures.
ConserVed Water Structure. Comparison of the active sites
shows that much of the water structure is conserved following
the binding of the inhibitors. The RXPA380 structure is at
a lower resolution to the other structures, but of the waters
modeled in the active site of this structure, all but one are
conserved in the other structures. The water interacting with
Lys 454 is not observed in the lisinopril and enalaprilat
structures because it is replaced by a glycine molecule. These
waters are scattered along the active site but clustered more
toward the S2 end of the active site (Figure 2D). The extra
length provided by the N-terminal Phe extending into the
S2 subsite also displaces two waters conserved between the
lisinopril and enalaprilat structures linked to the backbone
nitrogen of Ala 356 (Figure 2C). Two similar waters are also
seen in the captopril structure. The larger size of the
tryptophan moiety at the S2′ subsite also displaces a water
molecule conserved in the other three structures that interacts
with Gln 281 (Figure 2C).
Comparison with the N Domain of Somatic ACE.
RXPA380 was developed as a C domain-specific inhibitor
for comparison of the N and C domain catalytic sites in sACE
(18) with its Ki for the C domain 3000 times lower than that
for the N domain. Thus, it is interesting that the tACE
residues that form hydrogen bonds with RXPA380 are all
conserved in the N domain, although the aromatic interaction
with Phe 391 would be lost as this is replaced with Tyr 369.
Superposition of the N domain (Figure 3) with this structure
places the hydroxyl group of Tyr 369 within 2 Å of the P2
Phe moiety, illustrating that the same orientation for RX-
PA380 would not be possible in the N domain. The
combination of the lack of this interaction and the decrease
of hydrophobicity in the S2 subsite is likely to contribute to
the C domain selectivity of RXPA380.
However, potency comparisons of RXPA380 with other
phosphinic peptides suggest that the selectivity of RXPA380
for the C domain is due to its proline and tryptophan residues,
in the P1′ and P2′ positions, respectively. The tryptophan
moiety of RXPA380 is 4.5 Å from two valines (Val 379
FIGURE 1: Testis ACE with RXPA380. (A) Chemical structures
of RXPA380, enalaprilat, and captopril with the residue positions
(P2′, P1′, P1, and P2) labeled relative to the substrate-cleavage site.
The inhibitors are in the same orientation as in Figure 2. (B) Cartoon
of tACE (pink) showing RXPA380 (orange) bound in the active
site. The zinc and chloride ions are shown as green and red spheres,
respectively.
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and Val 380 in tACE) lining the S2′ subsite, making van der
Waals interactions with them likely. The change of these
residues to the polar Ser 357 and Thr 358 in the N domain
suggests that it is the decrease in hydrophobicity in this area
that makes the binding of RXPA380 to the N domain less
efficient.
It was also suggested that the NH of the indole ring of
the P2′ moiety may form a hydrogen bond with a nearby
aspartate (Asp 453 in tACE) and that this interaction may
be lost with the exchange of this residue for glutamate in
the N domain (25). However, Asp 453 is 5.5 Å away from
the tryptophan ring and is not close enough to make this
FIGURE 2: A close-up view of the tACE active site showing RXPA380 bound (orange). The zinc ion is shown in green, and (D) shows the
water molecules from the RXPA380 complex in light blue. Atoms are colored as follows: gray for carbon, red for oxygen, blue for
nitrogen, and purple for sulfur. (A) Omit map density (1ó, blue) for the inhibitor. Residues forming hydrogen bonds with the inhibitor are
shown as sticks with the hydrogen bonds represented as dashed red lines. A water molecule bound to the inhibitor is shown as a light blue
sphere. (B) The inhibitor captopril (blue) is superimposed on RXPA380. The sulfur atom can just be seen in yellow behind the purple
phosphorus atom of RXPA380. (C) Stereoview of enalaprilat (green) superimposed on RXPA380. Three waters that were observed in the
lisinopril and enalaprilat complex structures, but are displaced in the RXPA380 structure, are shown as light blue spheres with hydrogen
bonds illustrated as purple dashed lines. (D) Stereoview of waters in the RXPA380 complex active site. The view is rotated 90° from the
previous figures. Water-bound residues are shown as sticks and the waters as light blue spheres. Hydrogen bonds are illustrated as purple
dashed lines.
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interaction (Figure 3). Comparison with the N domain shows
that the equivalent glutamate is also over 4 Å away.
DISCUSSION
The currently available ACE inhibitors are well-established
therapeutics for high blood pressure and related diseases but
do not bind preferentially to either of the two domains of
somatic ACE. The binding strength for these inhibitors is
largely due to their ability to coordinate the zinc ion strongly
through sulfhydryl, carboxylate, or keto groups. Also, a
calorimetric study has shown that the binding of captopril,
lisinopril, and enalaprilat is entropically driven (35), which
may be the reason that inhibitors lacking the rigidity of the
prolyl moiety have reduced binding affinity (36). In contrast,
the phosphate moiety is a weaker coordinator of the zinc
ion, and this enhances the potential for selective inhibitors
whose binding strength is aided by their other substituents
(20). RXPA380 is the first example of a phosphinic peptide
that is truly selective for the C domain. To understand this
selectivity further and to probe the mechanism of this
preferred binding affinity, we have determined the crystal
structure of tACE, which is equivalent to the C domain of
sACE, complexed with RXPA380.
The structure reveals that the binding of RXPA380 to the
C domain involves more direct interactions than the previ-
ously determined ACE inhibitor structures. This can be partly
ascribed to the larger size of the inhibitor and may also be
required to compensate for the weaker coordination of the
zinc by the phosphate. Interestingly, the specificity of
RXPA380 for the C domain does not appear to depend on
hydrogen bonding to the protein, as all of these residues are
conserved in the N domain, but on the shape and polarity of
the active site. The exchange of three hydrophobic residues
(Phe 391, Val 379, and Val 380 in tACE) for polar residues
in the N domain (Tyr 369, Ser 357, and Thr 358, respec-
tively) results in the reduced affinity for the N domain
mediated by the P2 Phe and P2′ Trp moieties of RXPA380.
The question remains, however, whether other more drug-
like inhibitors can be designed to take further advantage of
differences between the two active sites. One obvious
difference between the sites is the presence of a positive
charge at the base of the S1′ pocket in the N domain. This
positive charge presumably contributes to the fact that
lisinopril, with its lysyl moiety at the P1′ position, is 20 times
more selective for the C domain than the N domain (8).
However, as enalaprilat, which lacks the lysyl group, also
has less affinity for the N domain, the contribution of this
moiety is hard to quantify.
More relevant, perhaps, is the increased hydrophobicity
of the S2′ pocket of the C domain, where it has been noted
that bulky P2′ residues, such as tryptophan, confer C domain
selectivity (36, 37). Although the Trp moiety utilizes this
space, there is still more space in this subsite for a larger
hydrophobic moiety extending toward Asp 453 (tACE
numbering). This extra space in the C domain, compared to
the N domain, is due to the larger Glu 431 in the N domain.
The other key difference, at the nonprime end of the binding
site, is the charge of the S2 pocket. The incorporation of the
bulky phenyl group at the P2 position contributes to the
selectivity of RXPA380 for the C domain due to the
presumed repulsion of this moiety by the larger Tyr 369 in
the N domain. However, the addition of a positive charge to
the P2 group may increase selectivity by ionic interactions
with this pocket in the C domain (Glu 403, tACE numbering)
and, similarly, repel the positive charge in the N domain
(Arg 381) (Figure 3). Indeed, the carboxylate group at this
position in the N domain-specific inhibitor RXP407 is known
to be one of the determinants of its specificity.
Another consideration, given the evidence for entropic
binding of captopril, lisinopril, and enalaprilat to the active
site, is the ability of new inhibitors to displace the water in
the active site. With a clearer understanding of the conserved
water structure of the active site, inhibitors could be designed
to displace extra waters at known sites. For example, a more
bulky P2′ residue may displace some of the conserved waters
in the extensive S2′ subsite, whereas an additional positive
charge on the P2 residue may favor interactions with Asp
358 at the expense of another conserved water (Figure 2D).
The necessity for drugs to meet many criteria such as
suitable solubility and bioavailability makes it hard to predict
which inhibitors will make good drugs in vivo. An effective
drug development strategy, where there are existing drugs
for a specific target, is the subtle modification of known
inhibitors in order to maintain drug-like properties. Thus, it
has been shown than even minor changes in ACE inhibitor
structures can lead to 1 or 2 orders of magnitude difference
in inhibition of N/C domain selectivity in vitro (36, 37). The
future of domain-specific ACE inhibitors lies in finding those
compounds that best utilize the chemical differences between
Table 2: Comparison of the Hydrogen Bonds between tACE and
Inhibitors RXPA380, Captopril, and Enalaprilat
tACE RXPA 380 captopril enalaprilat
residue atom atom
distance
(Å) atom
distance
(Å) atom
distance
(Å)
H353 NE2 O5 2.9 O1 2.5 O1 2.7
A354 O N1 3.0
A356 N O2 2.7
H383 NE2 O3 3.3
E384 OE2 S1 3.1 O2 2.7
H387 NE2 O4 3.0
K511 NZ O6 2.6 O2 2.7 O4 2.8
H513 NE2 O5 2.9 O1 2.7 O1 3.1
Y520 OH O6 2.6 O2 2.7 O4 2.6
Y523 OH O3 2.7 O3 2.8
W82 O OXT 3.0 O3 2.6 O5 2.7 FIGURE 3: Superposition of the tACE active site with the N domain.Residues unique to tACE/C domain are shown as pink sticks, and
the equivalent residues from the N domain are superposed as blue
sticks. The label colors match the residue colors, pink and blue for
tACE and the N domain, respectively.
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the domains while maintaining strong inhibition and drug-
like properties.
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